Surgicel® Fibrillar for Delayed Bleeding After ESD

Surgicel® (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study

The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors

1. Patient (1) Inclusion: Diagnosed as gastric dysplasia or early gastric cancer

   • Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia
   • Anti-platelet agents

2. Method

(1) Study group: combination with Surgicel® Fibrillar and H2RA (2) Control group: monotherapy with PPI 3. Sample size : 157 4. Result

1. Primary endpoint: rate of delayed bleeding after ESD
2. Secondary endpoint: follow-up hemoglobin after ESD

Inclusion Criteria:

• ESD for gastric dysplasia or early gastric cancer

Exclusion Criteria:

• Coagulopathy: liver cirrhosis, thrombocytopenia
• Anti-platelet agents